Nasus Pharma (NSRX) Change in Cash (2024)

Nasus Pharma (NSRX) posted Change in Cash of $706000.0 for Q4 2024.

Nasus Pharma (NSRX) Change in Cash (2024) Analysis & Trends

Nasus Pharma (NSRX) has reported Change in Cash for 1 consecutive years, with $706000.0 the latest figure, recorded in Q4 2024.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Change in Cash (Qtr)
1 Eli Lilly 1,066.16 Bn 1,060.88 Bn 16.22 Bn -1.99 Bn
2 Johnson & Johnson 611.69 Bn 589.64 Bn 15.96 Bn 1.98 Bn
3 AbbVie 444.34 Bn 434.99 Bn 10.78 Bn 4.16 Bn
4 Astrazeneca 284.94 Bn 277.05 Bn 12.61 Bn 5.70 Bn
5 Merck 224.23 Bn 218.58 Bn 12.09 Bn -9.29 Bn
6 Amgen 195.12 Bn 183.08 Bn 5.87 Bn 2.91 Bn
7 Gilead Sciences 156.45 Bn 148.73 Bn 5.52 Bn 65.00 Mn
8 Pfizer 136.01 Bn 123.24 Bn -1.21 Bn 563.00 Mn
9 Novartis Ag 113.45 Bn 113.67 Bn - -
10 Nasus Pharma 28.20 Mn 23.91 Mn - -

Historic Data

Download Data
DateValue
Dec 31, 2024 706,000.00